S&P 500
7,551.81
-33.92
-0.45%
Dow
51,461.90
-631.21
-1.21%
Nasdaq
25,978.42
-3.15
-0.01%
NYSE Composite
23,934.15
-194.31
-0.81%
Russell 2000
2,858.81
-11.47
-0.40%
VIX
17.71
+0.51
+2.97%
MEDS · DataMeds AI, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Wellgistics Health Inc (MEDS)
NASDAQ NMS - GLOBAL MARKET
Health Care
$6.07
+4.45
(+274.38%)
● At close: September 16 at 4:00:00 PM EDT
$6.96
+0.89
(+14.66%)
Overnight:
9:30:25 PM EDT
DAY'S RANGE
$6.07
$4.03
$12.31
52-WEEK RANGE
$6.07
$0.82
$3.88
What's happening
- MEDS is up 274.38% today, trading at $6.07. — Live quote
- It's trading within 3% of its 52-week high ($3.88). (Finnhub fundamentals)
- Volume today (880,081) is running 2.1x its 3-month average. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $-0.08 actual vs. $-0.22 estimated (+64.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MEDS
-75.83%
vs S&P 500
-77.63%
1-YEAR RETURN
MEDS
-34.17%
vs S&P 500
-42.16%
6-MONTH RETURN
MEDS
+21.75%
3-MONTH RETURN
MEDS
-21.00%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-04-26 (Q1 2026)
$-0.08
Est. $-0.22
BEAT +64.3%
2026-01-26 (Q4 2025)
$-0.11
Est. $-0.29
BEAT +61.5%
Valuation Measures & Ratios
Enterprise Value4$32.1M
Forward P/E5—
PEG Ratio6-0.00
Price / Sales (TTM1)0.34
Price / Book77.86
EV4 / Revenue18.03
EV4 / EBITDA—
Profit Margin-1100.30%
Operating Margin-1033.99%
Return on Equity (ROE8)-1645.88%
Return on Assets (ROA9)-241.65%
Avg Volume (3M)422,940
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $8.0M | $4.27B | $26.40B | $477.0M | $90.81B |
| P/E | -0.12 | -52.60 | -350.71 | -11.48 | -2597.78 |
| Price/Sales | 0.57 | 183.82 | 965.73 | 19.57 | — |
| Price/Book | -0.41 | -283.45 | 3895.55 | 526.88 | 20274.89 |
| EV/Revenue | 1.29 | 184.36 | 966.18 | 19.97 | — |
| ROE | 344.01% | 538.85% | -1110.78% | -4589.28% | -780.47% |
| ROA | -204.82% | -269.40% | -142.65% | -76.62% | -60.20% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short173,986
Change from Prior Settlement+5.54%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-31. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-18; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -77.2% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -1100.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -34.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MEDS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.6M | $3.0M | $7.8M | $10.9M | $5.7M | $44.5K | — |
| Gross profit | $182.2K | $170.2K | $231.0K | $505.8K | $692.6K | $521.2K | -$2.6K | — |
| Operating income | -$7.3M | -$6.0M | -$31.5M | -$5.5M | -$31.3M | -$1.7M | -$573.0K | -$79.8K |
| Net income | -$18.4M | -$7.7M | -$34.3M | -$6.7M | -$32.4M | -$1.9M | -$574.3K | -$83.1K |
| EPS (diluted) | $-7.13 | $-0.07 | $-0.46 | $-5.40 | $-0.62 | $-0.04 | $-0.01 | $0.00 |
| EPS (basic) | $-7.13 | $-0.07 | $-0.46 | $-5.40 | $-0.62 | $-0.04 | $-0.01 | $0.00 |
| Operating margin | -$413 | -$386 | -$1.0K | -$71 | -$289 | -$31 | -$1.3K | — |
| Net margin | -$1.0K | -$496 | -$1.1K | -$86 | -$299 | -$33 | -$1.3K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $32.8M | $30.1M | $30.5M | $52.8M | $54.2M | $58.1M | $57.3M | — |
| Total liabilities | $52.3M | $45.2M | $42.9M | $46.0M | $53.3M | $53.6M | $50.6M | — |
| Stockholders' equity | -$19.5M | -$15.1M | -$12.4M | $6.8M | $905.3K | $4.5M | $6.7M | $10.0M |
| Total current assets | $5.6M | $2.8M | $2.8M | $12.8M | $13.5M | $16.6M | $15.2M | — |
| Total current liabilities | $39.4M | $32.2M | $29.8M | $32.7M | $42.4M | $46.2M | $38.0M | — |
| Cash & equivalents | $2.5M | $51.7K | $42.6K | $4.2M | $419.9K | $2.5M | $1.0M | — |
| Accounts receivable | $1.2M | $992.1K | $1.1M | — | — | — | — | — |
| Inventory | $1.5M | $1.7M | $1.6M | $7.5M | $9.0M | $9.7M | $9.5M | — |
| Property, plant & equipment | $173.9K | $201.5K | $229.4K | $268.9K | $308.6K | $348.4K | $388.2K | — |
| Goodwill | $14.2M | $14.2M | $14.2M | $16.2M | $16.2M | $16.2M | $16.2M | — |
| Intangible assets | $2.9M | $2.7M | $2.5M | $2.2M | $2.0M | $1.9M | $1.6M | — |
| Other non-current assets | — | — | — | $1.5M | $1.4M | $1.4M | $1.4M | — |
| Short-term debt | — | — | — | $4.0M | — | — | — | — |
| Other current liabilities | — | — | $225.0K | — | — | — | — | — |
| Long-term debt | $12.6M | $12.6M | $12.6M | $12.6M | $10.1M | — | $11.5M | — |
| Common stock & paid-in capital | $283 | $11.9K | $203 | $8.9K | $6.3K | $6.1K | $5.1K | — |
| Retained earnings | -$137.1M | -$118.8M | -$111.0M | -$83.2M | -$48.9M | -$42.2M | -$9.8M | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.9M | -$3.4M | -$6.3M | -$1.1M | -$2.1M | -$1.3M | -$2.6M | $1.0M |
| Investing cash flow | -$242.1K | -$205.1K | -$255.4K | -$221.1K | -$131.9K | -$273.1K | $802.6K | -$315.9K |
| Financing cash flow | $5.5M | $3.6M | $2.4M | $5.2M | $114.3K | $3.1M | $2.1M | $4.5K |
| Share-based compensation | $1.2M | $1.4M | $355.7K | $25.7M | $935.2K | $27.8M | $1.1M | — |
| Change in accounts receivable | $302.3K | -$51.4K | $560.1K | -$996.9K | -$543.0K | $180.1K | $3.0K | $37.0K |
| Change in inventory | -$130.5K | $74.2K | $135.8K | -$1.5M | -$701.9K | $214.5K | -$294.7K | $383.2K |
| Change in accounts payable | $959.8K | $1.5M | -$1.9M | $960.0K | $1.3M | $1.9M | -$409.0K | -$269.3K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $23.3M | $18.1M | — |
| Gross profit | -$6.4M | $1.8M | — |
| Operating income | -$93.7M | -$6.1M | -$2.9M |
| Net income | -$101.3M | -$6.9M | -$2.9M |
| EPS (diluted) | $-1.43 | $-0.15 | $-0.06 |
| EPS (basic) | $-1.43 | $-0.15 | $-0.06 |
| Operating margin | -$402 | -$34 | — |
| Net margin | -$434 | -$38 | — |
Balance sheet
| Line item | Dec '25 | Sep '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $30.5M | — | $57.3M | $338.4K | — |
| Total liabilities | $42.9M | — | $50.6M | $3.2M | — |
| Stockholders' equity | -$12.4M | — | $6.7M | -$2.9M | -$5.2K |
| Total current assets | $2.8M | — | $15.2M | $338.4K | — |
| Total current liabilities | $29.8M | — | $38.0M | $2.9M | — |
| Cash & equivalents | $42.6K | — | $1.0M | $1.4K | — |
| Inventory | $1.6M | — | $9.5M | — | — |
| Property, plant & equipment | $229.4K | — | $388.2K | — | — |
| Goodwill | $14.2M | — | $16.2M | — | — |
| Intangible assets | $2.5M | — | $1.6M | — | — |
| Other non-current assets | — | — | $1.4M | — | — |
| Short-term debt | — | $4.0M | — | — | — |
| Long-term debt | $12.6M | — | $11.5M | — | — |
| Common stock & paid-in capital | $10.1K | — | $5.1K | $4.5K | — |
| Retained earnings | -$111.0M | — | -$9.8M | -$2.9M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$10.9M | -$1.2M | -$349.1K |
| Investing cash flow | -$881.5K | $469.1K | — |
| Financing cash flow | $10.8M | $1.8M | $350.5K |
| Share-based compensation | $54.8M | $1.1M | — |
| Change in accounts receivable | -$799.8K | $40.1K | — |
| Change in inventory | -$1.9M | $72.4K | — |
| Change in accounts payable | $2.2M | -$882.3K | $1.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MEDS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Set BUSINESSQUANT_API_KEY to enable institutional ownership.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 13 most recent filings · covers 2025-03-21 to 2026-06-22
Recent transactions
- Most recent: AJJARAPU SURENDRA K (Director) — In-the-money option exercise of 100,000 shares on 2026-06-22.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| AJJARAPU SURENDRA K | Director | In-the-money option exercise | 2026-06-22 | 100,000 |
| Patel Prashant | Chief Executive Officer | In-the-money option exercise | 2026-06-22 | 100,000 |
| PETERSON MICHAEL L | Director | Grant / award | 2025-07-02 | 200,000 |
| Pirani Shafaat | Chief Clinical Officer | Grant / award | 2025-03-21 | 35,000 |
| Syed Sajid | Director | Grant / award | 2025-03-21 | 200,000 |
| ANDERSON DONALD WILLIAM | Director | Grant / award | 2025-03-21 | 200,000 |
| Norton Brian | Chief Executive Officer | Grant / award | 2025-03-21 | 9,000,000 |
| Panchal Nikul | Chief Pharmacy Officer | Grant / award | 2025-03-21 | 90,000 |
| SHANAHAN REBECCA M | Director | Grant / award | 2025-03-21 | 200,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-22 | AJJARAPU SURENDRA K | Director | In-the-money option exercise | 100,000 | $0.01 |
| 2026-06-22 | Patel Prashant | Chief Executive Officer | In-the-money option exercise | 100,000 | $0.01 |
| 2026-03-31 | Patel Prashant | Chief Executive Officer | Grant / award | 5,000,000 | $0.20 |
| 2026-03-31 | AJJARAPU SURENDRA K | Director | Grant / award | 5,000,000 | $0.20 |
| 2025-07-02 | PETERSON MICHAEL L | Director | Grant / award | 200,000 | $0.90 |
| 2025-03-21 | Pirani Shafaat | Chief Clinical Officer | Grant / award | 35,000 | $0.00 |
| 2025-03-21 | Syed Sajid | Director | Grant / award | 200,000 | $0.00 |
| 2025-03-21 | AJJARAPU SURENDRA K | Director | Grant / award | 2,882,247 | $0.00 |
| 2025-03-21 | AJJARAPU SURENDRA K | Director | Grant / award | 600,000 | $0.00 |
| 2025-03-21 | AJJARAPU SURENDRA K | Director | Grant / award | 600,000 | $0.00 |
| 2025-03-21 | Patel Prashant | Chief Strategy Officer | Grant / award | 1,882,247 | $0.00 |
| 2025-03-21 | Patel Prashant | Chief Strategy Officer | Grant / award | 1,500,000 | $0.00 |
| 2025-03-21 | Patel Prashant | Chief Strategy Officer | Grant / award | 700,000 | $0.00 |
| 2025-03-21 | ANDERSON DONALD WILLIAM | Director | Grant / award | 200,000 | $0.00 |
| 2025-03-21 | Norton Brian | Chief Executive Officer | Grant / award | 9,000,000 | $0.00 |
| 2025-03-21 | Panchal Nikul | Chief Pharmacy Officer | Grant / award | 90,000 | $0.00 |
| 2025-03-21 | SHANAHAN REBECCA M | Director | Grant / award | 200,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-16 20:08 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-18 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-17 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-07-21 | 8-K | 2026-07-20 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-09 | View on SEC.gov → |
| 2026-05-29 | 8-K | 2026-05-27 | View on SEC.gov → |
| 2026-05-21 | 8-K | 2026-05-21 | View on SEC.gov → |
| 2026-05-21 | 8-K | 2026-05-19 | View on SEC.gov → |
Recent news
Headlines about MEDS (DataMeds AI, Inc.). Links open the publisher — we don’t host full articles.
-
DataMeds AI Acquires Helomics to Expand Cancer Platform
TipRanks · 2026-09-16 -
DataMeds AI Acquires Helomics From Axe Compute, Issuing 19.99% New Shares and $1.36M Note
TradingView · 2026-09-16 -
Sector Update: Healthcare Stocks Edge Lower Late Afternoon
Yahoo Finance · 2026-09-16 -
DataMEDS AI Jumps as Helomics Acquisition Expands Its Push Into Cancer Diagnostics
Quiver Quantitative · 2026-09-16 -
DataMEDS AI Completes $1.5 Million Helomics Acquisition, Expanding into Cancer Diagnostics
Yahoo Finance · 2026-09-16 -
MEDS Stock Rockets As DataMEDS AI Grabs Helomics Oncology Lab
timothysykes.com · 2026-09-16 -
DataMEDS Stock Prices a Helomics Deal Before Investors Get the Share Count
TechStock² · 2026-09-16 -
DataMeds AI (MEDS) Jumps As Helomics Deal Supercharges Oncology Push
stockstotrade.com · 2026-09-16
No headlines in this category right now — try “All”.